key: cord-0806016-gxrhrmid
authors: Bellio, Michael A.; Bennett, Cassie; Arango, Alissa; Khan, Aisha; Xu, Xiumin; Barrera, Cesar; Friedewald, Vincent; Mitrani, Maria Ines
title: Proof-of-Concept Trial of an Amniotic Fluid-derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection
date: 2021-11-24
journal: Biomater Biosyst
DOI: 10.1016/j.bbiosy.2021.100031
sha: 620b8158332ce3dcdf703090b5a17b083a0510c7
doc_id: 806016
cord_uid: gxrhrmid

A pandemic brought on by COVID-19 has created a scalable health crisis. The search to help alleviate COVID-19-related complications through therapeutics has become a necessity. Zofin is an investigational, acellular biologic derived from full-term perinatal amniotic fluid that contains extracellular vesicles. Extracellular nanoparticles as such have been studied for their immunomodulatory benefits via cellular therapeutics and, if applied to COVID-19-related inflammation, could benefit patient outcome. Subjects (n=8) experiencing mild-to-moderate COVID-19 symptoms were treated with the experimental intervention. Complete blood count, complete metabolic panel, inflammatory biomarkers, and absolute lymphocyte counts were recorded prior to and on days 4, 8, 14, 21, and 30 as markers of disease progression. Additionally, chest x-rays were taken of the patients prior to and on days 8 and 30. Patients experienced no serious adverse events. All COVID-19-associated symptoms resolved or became stable with no indication of disease worsening as found by patient and chest x-ray reports. Inflammatory biomarkers (CRP, IL-6, TNF- [Formula: see text]) and absolute lymphocyte counts improved throughout the study period. Findings from a proof-of-concept, expanded access trial for COVID-19 patients prove the acellular biologic is safe and potentially effective to prevent disease progression in a high-risk COVID-19 population with mild-to-moderate symptoms.

Patients with Severe Acute Respiratory Syndrome (SARS) coronavirus 2 (SARS-CoV-2), commonly referred to as the novel coronavirus of 2019, or COVID-19, were first diagnosed in December 2019 in Wuhan, China [1] . The disease rapidly spread across the globe and was declared a pandemic on March 11, 2020 , by the World Health Organization (WHO). Despite the availability of vaccines, the disease incidence, hospitalizations, and deaths persist at a high level largely attributable to the delta variant of mid-2021 that involves younger and healthier populations than originally seen [2] .

The most common initial manifestations of COVID-19fever, cough, muscle pain, nausea, and vomitingare due to viral entry into the upper respiratory tract via the ACE-2 receptor [3, 4] . The virus then undergoes local replication and propagation, while infecting ciliated cells in the conducting airways [5] . During this time, an incubation stage persists for approximately 5 days with an early, limited immune response [6] . After virus incubation, a period of mild-to-moderate symptoms can occur to the majority of those infected within 14 days following exposure [6, 7] . After initial infection of the upper respiratory tract, the lungs become a primary target as the disease progresses [8] . Lung complications from COVID-19 can range from pulmonary edema, endothelial and epithelial damage, acute lung injury, and pulmonary fibrosis [8] [9] [10] [11] . The lungs have the capability to regenerate and heal up to a certain threshold of damage; however, significant damage to the lungs often results in irreversible fibrotic scarring and latter functional complications [12] .

In some personsespecially those with increased risk factorsan even more severe, multi-organ disease develops, affecting the heart, kidneys, blood coagulation, and central nervous system [7, 13] . The risks factors, or comorbid conditions, that exist and contribute to the host's increased risk for developing severe COVID-19 and retrospective complications are the following: obesity, systemic arterial hypertension, chronic obstructive lung disease, and diabetes mellitus [14] . To note, obesity stands out as having the strongest connection to risk [14, 15] .

Despite understanding COVID-19 transmission and clinical manifestations, the precise pathophysiology of COVID-19 human infection is uncertain and the subject of intense, ongoing investigation [16] . The catalyst at the forefront of COVID-19's initiation and ramification has been postulated as systemic hyper-inflammation, referred to as a "cytokine storm" [17] . An amplified immune response, however, can promote further inflammation to the site, leading to detrimental, self-destructive effects that can overwhelmingly damage the lungs [18] [19] [20] [21] .

Inflammation is thus a primary target of therapeutic interventions for COVID-19 in both its early and late stages [22, 23] .

Mechanistically, therapeutic agents can be categorized as (i) those that aim to target the viral life cycle, such as remdesivir or lopinavir-ritonavir; (ii) SARS-CoV-2-targeted antibody therapies; and (iii) those that are focused on the host response, such as glucocorticoids and other immunomodulators [24] . Dorward et al [25] have suggested using an immunomodulator to target COVID-19-associated inflammation rather than targeting the pathogen load itself could more effectively reduce the progression of COVID-19 immunopathology. Additionally, McCullough et al [26] have proposed that therapeutic approaches based on pathophysiologic principles for early treatment of COVID-19 include the (i) reduction of reinoculation, (ii) combination antiviral therapy, (iii) immunomodulation, and (iv) antiplatelet/antithrombotic therapy. The study described herein is based on immunomodulation.

This investigation is a proof-of-concept trial in which the investigators hypothesize that the study drug, Zofin, possesses immunomodulatory properties that are (i) safe, (ii) ameliorate inflammation in mild-to-moderate COVID-19 patients sufficient to prevent disease progression, and (iii) demonstrate the anti-inflammatory preventative effect by reduction in surrogate inflammatory markers. Zofin is an acellular biologic derived from full-term perinatal amniotic fluid (AF) containing soluble paracrine factors and insoluble extracellular nanoparticles. AF and its components have been hypothesized as being beneficial for regenerative medicine in part due to promoting anti-inflammatory properties, where studies have demonstrated the therapeutic potential of AF-derived stem cells and extracellular vesicles [27] [28] [29] [30] . Because of the correlation between COVID-19 and a pro-inflammatory state, common first-line treatments include antiinflammatory agents [31, 32] . With previous demonstration of safety, evidence of antiinflammatory effects, and possible efficacy in treating severely ill COVID-19 patients [33] , Zofin has the potential to prevent disease progression.

Here within are the findings of a proof-of-concept, expanded access trial for high-risk patients with mild-to-moderate COVID-19 infection to investigate (i) the primary outcome, the safety of Zofin as an intravenous (IV) therapeutic, (ii) the secondary outcomes, the efficacy of Zofin on surrogate inflammatory biomarkers and patient outcomes and (iii) whether the results justified further testing in large scale, controlled clinical trials of similar patients who are at high risk for disease progression.

This study involving human participants was reviewed and approved by the 

The therapeutic intervention studied in this proof-of-concept trial is a trademarked allogenic, acellular biologic called Zofin containing AF-derived extracellular vesicles. Zofin is manufactured by Organicell Regenerative Medicine, Inc. in Miami, FL, as previously described [5] . Zofin is derived from human AF donated from consenting adults during routine, planned cesarean sections under IRB approved donor screening (IRB approval agency: IRCM). The final Zofin product was released by Organicell Regenerative Medicine, Inc., after meeting the release criteria requirements. The product specifications, based on specific release criteria, for Zofin administered in these treatments were as follows: sterility (14-day cultures: no growth for aerobic, anaerobic, and fungal contamination), endotoxin (<0.25 EU/mL), nanoparticle composition (concentration=2.63x10 11 nanoparticles/mL), mode particle (size=99.7 nm), protein concentration (1.084 mg/mL), and hyaluronic acid concentration (196 ng/mL). Supplement figure 1 shows the nanoparticle tracking analysis of Zofin performed by a NanoSight NS300 (Malvern Panalytical, Malvern, UK).

Patient evaluation, testing, and product infusion were performed in a single outpatient site at United Memorial Medical Center (UMMC) in Houston, TX throughout the months of March and June 2021. Study subjects were contacted by phone in chronological order the next day following testing positive for COVID-19 in the UMMC clinic. About 50% declined to participate, primarily for travel reasons. Eleven subjects were enrolled between the ages of 35 and 69 years who had mild-to-moderate COVID-19 symptoms as defined by the inclusion criteria (Table 1) . Patient enrollment was completed following successful screening, which included COVID-19 testing and symptom checking. Qualified patients were scheduled for baseline (BSL) treatment up to 72 hours after screening. The study duration was 30 days followed by a phone call at 90 days post-infusion. Subjects received an intravenous infusion of 1 ml of Zofin diluted in 100 mL of normal saline on day 0 (baseline), day 4, and day 8, respectively, for a total of three treatments of Zofin. Patients received in-person follow-ups on day 0 (baseline), day 4, day 8, day 14, day 21, and day 30 and a phone call follow-up on day 90.

One patient withdrew before receiving any doses of Zofin and 2 subjects were unwilling to come to the study site after receiving the initial 3 infusions. In total, 8 subjects completed the followups and are therefore included in the data analysis ( Table 2 ). The patient population contained patients with a mean BMI of 31.2 ± 4.8. Most of the patients had a BMI considered to be obese with others being overweight and only 1 normal weight. Three of the eight subjects had comorbidities with two of them taking associated medications. Patients 001, 004, and 010 had a medical history of arthritis and osteoporosis; arthritis, gout, type-2 diabetes, and hypertension; and type-2 diabetes, hypertension, and asthma, respectively. Patients 004 and 010 were actively taking medications prescribed by their physicians to address the listed comorbidities. (Note: The 2 subjects who received infusions but did not complete the follow-ups have been contacted by phone 90 days post-infusion and stated that they have fully recovered with no adverse effects.) N=5 *Data was presented as mean ± SEM or count.

Qualitative detection of COVID-19 was performed using BD universal viral transport kit.

Specimens were obtained by nasopharyngeal swab and analyzed by real time-polymerase chain reaction (RT-PCR) methodology at a CLIA certified laboratory. Testing was completed from screening and every visit thereafter until a COVID-19 negative result was obtained.

For women of child-bearing potential only, agree to use FDA-recommended birth control until 6 months post treatment 

Blood collection and testing for complete blood count (CBC), complete metabolic panel 

At each visit from the time of screening and thereafter, patients were asked to report the presence of cough, fatigue, and shortness of breath, in addition to any new symptoms or change in original symptoms. A pulse oximeter was placed on the index finger and the blood oxygen saturation was recorded at each visit. Vital signs, including heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, and temperature, were recorded at screening and all following visits. The patients were strictly monitored 15 minutes prior to the initiation of the infusion, during the infusion, and for a minimum of 2 hours post-infusion.

A portable chest x-ray (CXR) was used to acquire imaging at baseline (day 0, prior to treatment), day 8, and day 30 to evaluate, identify, and monitor lung abnormalities [34] . After images were acquired, analysis was performed by a staff radiologist at UMMC, and CXR reports were generated to describe the clinical findings.

Statistical differences were calculated using a repeated measures one-way ANOVA test.

If statistical significance was found, a Tukey test was used to determine the post hoc analysis.

Data analysis was completed using full data sets (n=8). For example, incomplete data (n<8) for TNF-α and IL-6 at BSL resulted in the removal of that time point for statistical analysis of both biomarkers, and analysis was performed on the complete data sets starting at day 4. For the percent change analysis, patient 003 was excluded for CRP and IL-6 due to an outlier and incomplete data, respectively, resulting in an n-value of 7. Data is presented as the mean ± standard error of the mean (SEM). Figure assembly and data analysis were performed using Prism9 software (GraphPad Software, LLC).

During product administration and throughout the study period, no serious adverse events were reported. CBC results were analyzed for each patient and indicated no abnormalities of concern (Supplement Figure 2) . Similarly, CMP results were collected and analyzed per patient and demonstrated no findings of concern (Supplement Figure 3 ).

At the time of patient screening, all patients were confirmed positive for COVID-19

infection. COVID-19 testing was repeated at day 4 and subsequent visits until a negative test result was obtained ( Figure 1A ). All patients resolved from the COVID-19 infection within the 30-day visit period. Five out of 8 patients reported a cough at screening. By the 30-day visit, cough was resolved in 3 out of 5 patients ( Figure 1B ). While 6 out of 8 patients originally reported fatigue at screening, the fatigue resolved by day 14 ( Figure 1C ). Shortness of breath was reported by 1 patient at screening, which resolved by day 8, and 1 patient at day 4, which resolved by day 30 ( Figure 1D ). Pulse oximetry testing of each patient demonstrated 2 patients below normal O2 saturation at screening, 3 patients below normal O2 saturation between day 4 to day 21, and 1 patient with lower than normal O2 saturation at the final 30-day visit ( Figure   1E ). The respiratory rate, or breaths per minute, were recorded for all patients ( Figure 1F ), and per analysis, a significant decrease was found for the respiratory rate percent change as compared from screening to day 30 (-20.5% ± 4.3% P-value <0.05)( Figure 1G) . 

Chest x-ray (CXR) images were taken at baseline, day 4, and day 30 to observe the presence of pulmonary abnormalities (Figure 2A) . Baseline images demonstrated that 3 out of 8 patients had pulmonary observations or findings prior to Zofin infusion, whereas 6 out of 8 patients had observed pulmonary findings at day 4. By day 30, 3 out of 8 patients had observable pulmonary findings ( Figure 2B ). The patients individual CXR and CXR analysis statements (Supplement Figure 4) were collected at each time point to demonstrate and describe the pulmonary findings indicated in Figure 2B . Inflammatory biomarker testing included CRP, D-Dimer, IL-6, and TNF-throughout the study period. At baseline, 5 out of 8 patients had high levels of CRP concentration with 2 patients having increased levels of CRP by the end of the study period ( Figure 3A) . The percent change of CRP significantly decreased at the 14-day (-81.1% ± 7.3%, P-value <0.001) and 21day (-78.0% ± 10.9%, P-value <0.01) time points as compared to BSL ( Figure 3B ). D-Dimer was not found to be outside of the normal range for any of the patients at baseline or throughout the study period, and no significant differences between the percent changes were found ( Figure   3C and D). IL-6 measurements were performed at baseline and throughout the study period;

however, samples lost for 4 patients at baseline and 1 patient at day 4 reduced the number of complete data sets to be analyzed. Analysis of the complete data sets from day 4 onward found 4 out of 7 patients with elevated IL-6. IL-6 was not elevated in any of the patients by day 14 and thereafter ( Figure 3E ). The percent change of IL-6 in the 7 patients with complete data sets from day 4 showed a significant decrease at day 14 (-77.9% ± 5.2%, P-value <0.0001), day 21 (-81.4% ± 4.5%, P-value <0.0001), and day 30 (-75.7% ± 5.3%, P-value <0.0001) ( Figure 3F ).

Similarly, TNF-measurements were performed; however, samples lost for 3 patients at baseline reduced the number of complete data sets to be analyzed. Higher than normal TNFwas found in 2 out of 8 patients at day 4 ( Figure 3G ). Analysis of the percent change from day 4

found TNF-to be significantly reduced from day 4 to day 30 (-33.8% ± 5.8%, P-value <0.01) ( Figure 3H ). 

The ALC was calculated using the total WBC count and lymphocyte percentages collected with the CBC analysis. At baseline, all patients were within the normal range of ALC but trended towards the lower limit ( Figure 4A ). Throughout the study period, ALC gradually increased with a significant increase by day 14 (51.5% ± 12.8%, P-value <0.05) and day 30

(62.8% ± 16.4%, P-value <0.05)( Figure 4B ).

The most important goal of treating patients with mild-to-moderate COVID-19 infection is to prevent progression, which, when it occurs, usually requires hospitalization, sometimes accompanied with ventilator assistance, intubation, and death in 40% of those reaching a critical stage [35] . Currently, for ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the Infectious Disease Society of America guideline panel suggests only bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab, which is a A B conditional recommendation with moderate certainty of evidence [36] . Thus, the development of novel therapeutics is vital.

As a biological agent, Zofin is hypothesized to ameliorate COVID-19 infection via its perinatal-derived immunomodulatory and anti-inflammatory properties. Zofin's composition, which is derived from perinatal tissue paracrine factors, contains two fractions believed to contribute to its therapeutic potential and ultimately its mechanism of action: extracellular vesicles (EVs) and soluble proteins/extracellular matrix components. In nature, AF contains components that play various roles in fetal immunity, development, and overall homeostasis [37] . Some of the components of AF that have been characterized include its proteomics and cell types, including AF stem cells. Proteomics of AF reveal that the majority of its proteins reside extracellularly and share similarity with specific organ tissues with the lung being the third out of the top ten tissues [38] . Mesenchymal stem cells from AF and their paracrine factors have been proven to have a regenerative effect in multiple organs, including the lungs [39, 40] , highlighting the potential of perinatal cells to be beneficial in cell therapeutics. Of special importance to COVID-19, mesenchymal cells of different origin have been used to treat disease models of the lung such as pulmonary arterial hypertension and acute lung injury [41, 42] . However, the mechanism of action from cell-derived therapies has been linked to the cells' secreted factors, such as paracrine factors [39] or exosomes and EVs [42] . As an acellular biologic, Zofin's therapeutic potential likely resides in the EVs, nanoparticles, and paracrine factors found in AF and thus incorporates the perinatal tissue's inherent protective and immunomodulatory ability.

Preclinical data investigating the therapeutic potential of Zofin's EV fraction in a neonatal lung injury model demonstrated the product's immunomodulatory and anti-inflammatory properties [30] . When delivered by intratracheal injection, high oxygen-damaged lungs are protected from tissue injury concurrent with a reduction in macrophage invasion and suppression of proinflammatory cytokine expression [30] . Preclinical testing of other EV biologics in large animals has established effective EV/nanoparticle single doses ranging from 1x10 11 to 3x10 12 particles / dose [43, 44] . The Zofin dose tested within this study contained a nanoparticle concentration of 2.6x10 11 particles / dose and fell within this referenced range. Together, these findings provide critical developmental insight into Zofin's mechanistic regulation of an inflammatory response during pulmonary injury.

Zofin has previously been approved for testing in a phase I/II clinical trial for patients with moderate-to-severe acute respiratory distress syndrome related to COVID-19 infection (Clinicaltrials.gov identifier: NCT04384445); this study population represents those patients with moderate-to-severe COVID-19 who are hospitalized but not yet intubated. Similarly, single patient emergency use authorizations were also approved to treat severe cases of acute respiratory distress syndrome induced by COVID-19 [33] . In continuation of these studies, expanded access was granted by the FDA to test Zofin in this discussed population of patients with milder disease. Mild-to-moderate, addressed within this study, and moderate-to-severe illness represent two distinct populations of patients at various stages of COVID-19 infection.

This proof-of-concept expanded access trial sought to primarily determine the safety of Zofin when administered intravenously to mild-to-moderate COVID-19-infected patients in addition to observing its efficacy via patient outcome, inflammatory biomarker status, and absolute lymphocyte count (ALC). All subjects were closely observed for adverse events and serious adverse event: no serious adverse events were observed throughout the study. Vital signs including heart rate, body temperature, and blood pressure (data not shown) as well as CBC and CMP tests were conducted to monitor the treatment's influence on overall patient health. No areas of concern were derived from these parameters, and the effect of Zofin via IV therapy for mild-to-moderate COVID-19 patients was concluded to be safe.

The presence and severity of COVID-19 infection within the lungs and their capacity to function is central to its pathophysiology [8, 9] ; thus, pulmonary symptoms such as cough and shortness of breath as well as fatigue were carefully monitored as measures of outcome. The length of time necessary for patients to test negative for COVID-19 and to exhibit symptom onset and/or recovery varied. COVID-19 so far has demonstrated itself to have a varying disease phenotype in addition to symptom heterogeneity in patients [45] , which could contribute to the variable outcomes as seen in Figure 1 . Nonetheless, by the end of the study, all patients tested negative for COVID-19, and a majority resolved from all associated symptoms, not including 2 out of the 8 patients who experienced a lingering cough. Image qualification of the patients' lungs further supported an improvement in patient outcome for the majority. Seven patients exhibited pulmonary findings. Four of the 7 patients resolved pulmonary findings by day 30, while 3 of the 7 patients completed the study with unresolved pulmonary findings. None of the patients displayed pulmonary worsening by day 30; therefore, no COVID-19-induced lung findings progressed throughout this study. Additionally, the respiratory rate significantly decreased throughout the study, suggestive of an improvement to lung health.

The induction of prolonged inflammation is associated with COVID-19 infection severity and worsening [18, 19] . Regardless of the viral RNA and protein presence of COVID-19 within multiple organs, inflammation has been reported to aggregate predominantly in the lungs [25] .

Additionally, a reduction in ALC as an indication of leukopenia has been observed in COVID-19 patients and found to correlate with disease severity [46] . Therefore, measurement of proinflammatory cytokines and ALC as COVID-19 disease surrogate markers throughout injury progression in addition to lung pathology are critical components in COVID-19 patient outcome.

Although the study population had elevated concentrations of CRP, IL-6, and TNF-at either baseline or the earlier time point of day 4, analysis found significant decreases in all three inflammatory cytokines. Additionally, ALC levels originally trended towards the lower limit but elevated with a maximum percent change at the endpoint of the study. These results indicate inflammation subsided and ALC levels were stabilized, which lessened inflammatory-related disease severity for COVID-19 patients.

A special note must be made about the role of obesity in this study. Although body weight was not a factor in the inclusion or exclusion criteria, all but 1 of the 8 patients reported were overweight with most being overtly obese. Over 73% of Americans aged ≥20 years are overweight, including 42.5% who are obese [47] ; therefore, a majority of the study population having excess weight was unsurprising. The finding that almost all study patients were overweight was not realized until conducting data analysis after the study had been completed (90 days after initial infusion for all study patients). The importance of this demographic is that obesity has emerged as a strong risk factorperhaps second only to advanced agefor hospitalization among persons with acute COVID-19 [48, 49] . Obesity, which is a component of the metabolic syndrome, is associated with the secretion of inflammatory adipokines [50, 51] .

The role of inflammation in COVID-19 disease progression is thus magnified in obese individuals, and this study, regardless of the population's high risk, established evidence to attenuate COVID-19-associated inflammation. Aside from obesity, additional comorbidities existed within three of the patients with two patients actively being treated for their medical conditions. The prescribed medications were unrelated to COVID-19 treatments and unlikely to be interactive with COVID-19-related therapeutics. Because only a minority of the patients were treated with their comorbidity-prescribed medications, we do not believe the medications had a strong influence on patient outcome.

Results of this proof-of-concept study, particularly the significant trending effect of Zofin on inflammatory biomarkers and ALC, suggests that Zofin provided a safe and efficacious therapeutic to prevent COVID-19 progression to more serious stages. Although COVID-19 was in the mild-to-moderate stage at the time of initial treatment, some patients in this cohort could have worsened throughout the treatment course by chance, which was not observed. Analysis of patient outcomes, including COVID-19-associated symptoms, chest x-ray images, and inflammatory biomarkers demonstrated the beneficial outcomes that may indicate Zofin's efficacy and therapeutic value for preventing disease progression. Because the patient size was relatively low and lacked a placebo control, these results warrant further investigation in a larger, randomized and placebo-controlled study; however, evidence supports Zofin's ability to prevent disease progression for this generalized cohort of mild-to-moderate COVID-19 patientsespecially those with a high-risk factor of obesity. The completed study supports Zofin as a feasible, safe, and potentially efficacious therapy for patients with mild-to-moderate COVID-19 who are at increased risk for progression, including the need for hospitalization, ventilation, and death.

A new coronavirus associated with human respiratory disease in China

Delta coronavirus variant: scientists brace for impact

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

The pulmonary pathology of COVID-19

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential

Regeneration and repair in the healing lung

Nervous system involvement after infection with COVID-19 and other coronaviruses

Predictors of COVID-19 severity: A literature review

Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment

COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies

COVID-19: immunopathogenesis and Immunotherapeutics

Hyperinflammation and Immune Response Generation in COVID-19

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Sepsis: Inflammation Is a Necessary Evil

Anti-inflammatory therapy for COVID-19 infection: the case for colchicine

Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19

JAK Inhibitors -More Than Just Glucocorticoids

Tissue-Specific Immunopathology in Fatal COVID-19

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications

Amniotic fluid-derived stem cells in regenerative medicine research

Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?

Amniotic fluid-derived extracellular vesicles: characterization and therapeutic efficacy in an experimental model of bronchopulmonary dysplasia

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients

Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review

COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis

Infectiour Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Amniotic Fluid: Not Just Fetal Urine Anymore

Proteomics analysis of human amniotic fluid

Amniotic Fluid Stem Cells Rescue Both in Vitro and in Vivo Growth, Innervation, and Motility in Nitrofen-Exposed Hypoplastic Rat Lungs through Paracrine Effects

Human Amniotic Fluid Stem Cells Can Integrate and Differentiate into Epithelial Lung Lineages

Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats

MSC-derived exosomes: a novel tool to treat therapy-refractory graftversus-host disease

Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction

Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease

COVID-19: Why does disease severity vary among individuals?

Analysis of absolute lymphocyte count in patients with COVID-19

Obesity as a risk factor for hospitalization in COronaVirus Disease-19 (COVID-19) patients: Analysis of the Tuscany regional database

How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre

Obesity and inflammation: the linking mechanism and the complications

Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution

This clinical trial and its research were sponsored by Organicell Regenerative Medicine.

The raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.